Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kendle International Inc. (KNDL) -- Ignore unavailable to you. Want to Upgrade?

To: D. K. G. who wrote (31)	8/15/1998 2:33:00 PM
From: raydit	Respond to of 53

I got on to KNDL when I noticed it as stock of the week on S&P's personalwealth.com. I have a position in Chesapeake Biological Labs, a Baltimore firm in the same business. CBLI has just completed a new facility in Camden Yards for testing and production of drugs. Earnings averaged 11 cents for three years, with a loss of 8 cents on the 5 million shares in the 1998 year (3/31). I am much more impressed with KNDL for reason that it has a global presence whereas CBLI is only in Baltimore. CBLI's last stock offering was in June, 1997 at about $3.50 per share. It went to about 6, then 7, and was at its high of about 8.5 two weeks ago, then fell off to below 6; now its back to 6.5. The analyst at Ferris, Baker expects 20 cents this year and 70 cents the following year - if new business develops as expected. I do not follow Quintiles, which I understand is the industry heavyweight.